bioRxivBioengineering
Delta-1 functionalized hydrogel promotes hESC-cardiomyocyte graft proliferation and maintains heart function post-injury
K. A. Gerbin, K. A. Mitzelfelt, X. Guan, A. M. Martinson, C. E. Murry
Abstract
Current cell transplantation techniques are hindered by small graft size, requiring high cell doses to achieve therapeutic cardiac remuscularization. Enhancing the proliferation of transplanted human stem cell-derived cardiomyocytes (hESC-CMs) could address this, allowing an otherwise subtherapeutic cell dose to prevent disease progression after myocardial infarction. Here, we designed a hydrogel that activates Notch signaling through 3D presentation of the Notch ligand Delta-1 to use as an injectate for transplanting hESC-CMs into the infarcted rat myocardium. After four weeks, hESC-CM proliferation increased 2-fold and resulted in a 3-fold increase in graft size with the Delta-1 hydrogel compared to controls. To stringently test the effect of Notch-mediated graft expansion on long-term heart function, a normally subtherapeutic dose of hESC-CMs was implanted into the infarcted myocardium and cardiac function was evaluated by echocardiography. Transplantation of the Delta-1 hydrogel + hESC-CMs augmented heart function and was significantly higher at three months compared to controls. Graft size and hESC-CM proliferation were also increased at three months post-implantation. Collectively, these results demonstrate the therapeutic approach of a Delta-1 functionalized hydrogel to reduce the cell dose required to achieve functional benefit after myocardial infarction by enhancing hESC-CM graft size and proliferation.
- organism: rat
- assay: bulk RNA-seq
- research focus: cancer & tumor microenvironment
- research focus: cell type annotation
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- In situ maturated early-stage human induced pluripotent stem cell-derived cardiomyocytes improve cardiac function by enhancing segmentary contraction in infarcted rats
D. Biagi, E. T. Fantozzi, … R. Dariolli·bioRxiv·Mar 9, 2021
- Human induced pluripotent stem cell-derived three-dimensional cardiomyocyte tissues ameliorate the rat ischemic myocardium by remodeling the extracellular matrix and cardiac protein phenotype
J. YOKOYAMA, S. Miyagawa, … Y. Sawa·bioRxiv·Jan 5, 2021
- Cell therapy with human iPSC-derived cardiomyocyte aggregates leads to efficient engraftment and functional recovery after myocardial infarction in non-human primates
I. Gruh, A. Martens, … U. Martin·bioRxiv·Dec 31, 2023
- Immature human engineered heart tissues engraft in a guinea pig chronic injury model
C. von Bibra, A. Shibamiya, … F. Weinberger·bioRxiv·Jul 7, 2022
- Contractile force of transplanted cardiomyocytes contributes to heart function after injury
T. Stuedemann, J. Roessinger, … F. Weinberger·bioRxiv·Nov 23, 2021
- Immunomodulatory effect of HLA-G Overexpressed Mesenchymal Stromal Cell in Cell-based Therapy for Myocardial Infarction